Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)

NCT05963984 is registered in ClinicalTrials.gov with Carrick Therapeutics Limited as lead sponsor.

NCT NCT05963984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05963984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Interventional, Multicenter, Randomized, Phase 2 Study of Fulvestrant With or Without Samuraciclib in Participants With Metastatic or Locally Advanced Hormone Receptor (HR) Positive and Human Epidermal Growth Factor Receptor (HER)2-Negative Breast Cancer (BC)
Lead sponsor
Carrick Therapeutics Limited
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2023
Completion date
August 28, 2025
Enrollment
60 (actual)
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, locally advanced breast cancer, metastatic breast cancer